Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.
- Four-year exclusive global distribution agreement with EZZ Life Sciences
- Minimum sales target of $10 million over the contract term
- Focus on high-margin nutraceutical products including EZZ Glutathione Health Support
- Cooperative manufacturing model to ensure healthy margins
- Strategic alignment with Aumake’s planned rebranding to Xenitra
Strategic Partnership Expands Global Reach
Aumake Limited (ASX, AUK) has formalised a significant four-year exclusive global distribution agreement with EZZ Life Sciences (ASX, EZZ), aiming to generate a minimum of $10 million in sales. This deal marks a pivotal step for Aumake as it leverages its proven sales channels to distribute a range of high-value nutraceutical products worldwide.
The agreement grants Aumake exclusive global rights to distribute key EZZ products such as EZZ Glutathione Health Support, EZZ Vitality Boost, and EZZ Sleep. These products fall within the highest margin segment of Aumake’s Nutritionals channel, promising to enhance profitability through both B2B and B2C sales platforms.
Building on Proven Sales Momentum
Since 2025, Aumake has recorded over $2.1 million in sales across wholesale and direct-to-consumer channels, demonstrating its capability to drive growth in the competitive nutraceutical market. The new agreement not only builds on this momentum but also introduces a cooperative manufacturing model designed to maintain healthy margins while expanding product offerings.
Chairman Dr Anthony Noble emphasised the importance of compliance and streamlined commercial processes implemented in 2026, which have been instrumental in securing this deal. He expressed optimism that this partnership will serve as a proof point for attracting further collaborations, particularly in the lucrative Chinese e-commerce and retail distribution markets.
Global Exclusivity and Market Focus
The exclusive distribution rights cover all channels globally, with a particular focus on meeting demand in China through co-developed products tailored for that market. The agreement includes minimum annual sales targets of $2.5 million, with failure to meet these targets resulting in automatic termination of exclusivity.
Looking ahead, Aumake is seeking shareholder approval to rebrand as Xenitra (ASX, XEN), reflecting its broader ambitions across products and markets. This rebranding is expected to coincide with the rollout of the newly distributed EZZ products, signalling a new chapter in the company’s growth trajectory.
Implications for Investors and the Sector
This deal highlights the growing importance of nutraceuticals within the consumer staples sector, particularly products that combine health benefits with strong margin potential. Aumake’s strategic alignment with EZZ Life Sciences positions it well to capitalise on expanding global demand, especially in Asia.
While the agreement sets clear sales targets, execution risks remain, particularly in navigating regulatory environments and consumer preferences in key markets. Nonetheless, the partnership underscores Aumake’s revitalised commercial strategy and its intent to become a leading distributor in the nutraceutical space.
Bottom Line?
Aumake’s exclusive deal with EZZ could redefine its growth path, but execution in key markets will be critical.
Questions in the middle?
- How will Aumake manage regulatory challenges in China’s nutraceutical market?
- What new products might be co-developed under this agreement to meet market demand?
- How will the upcoming rebranding to Xenitra impact investor confidence and market positioning?